Background: This study aimed to elucidate the clinical features and prognostic factors of
| INTRODUCTION
Mesenchymal chondrosarcoma (MCS), first described by Lichtenstein and Bernstein in 1959, is a rare high-grade malignancy of the bone or soft tissues. 1 MCS exhibits a unique biphasic histology, which includes a well-differentiated cartilaginous matrix and a small, undifferentiated, round cell component. Several studies have described the clinical characteristics of MCS. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] MCS differs from conventional chondrosarcoma (CCS) in terms of the patient age distribution, primary site, and prognosis. MCS typically occurs in young adults, and approximately 30% of cases occur in the soft tissues. In contrast, most CCS patients are aged ≥50 years and extraosseous CCS accounts for <1% of all cases.
The European Musculoskeletal Oncology Society (EMSOS)
recently reported prognostic factors for 113 cases with MCS and concluded that a complete excision and adjuvant chemotherapy was considered to be the standard treatment for localized
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disease. 16 However, there are only two studies to date that could analyze the clinical characteristics and prognostic factors in a sample size exceeding 50 patients with MCS. 16, 18 Consequently, our understanding of MCS is still extremely limited in terms of the clinical characteristics, treatment outcome, prognostic factors, and in particular, the roles of chemotherapy and radiation therapy.
Therefore, we conducted a Nation-wide survey on patients with MCS in cooperation with the Japanese Musculoskeletal Oncology Group (JMOG). This study aimed to elucidate the clinical characteristics, treatment outcomes, prognostic factors, and roles of chemotherapy and radiation therapy in MCS. Himeji Red Cross Hospital, Hiroshima University, Nagoya University, Nara Medical University, Niigata University, Teikyo University, Tokyo University, and Osaka National Hospital. This study was approved by the Institutional Review Board of each participating hospital. All diagnoses were histologically confirmed by specialist pathologists in each hospital. 19 Patients received multi modal treatment, including surgery, radiation therapy, and chemotherapy. Excision of the primary tumor with a negative surgical margin was attempted whenever possible. The microscopic surgical margin was determined histologically using the resected specimens and was classified as either All time-to-event endpoints were calculated using the Kaplan-Meier method. Survival analysis was calculated from the day of diagnosis, and potential prognostic factors were identified by univariate analysis using the log-rank test. Independent prognostic factors were evaluated using the Cox proportional hazards regression model. Proportions of variables among the sites of origin were compared using chi-square tests. A two-tailed probability (P) value of <0.05 was considered to be statistically significant. Statistical analyses were performed using SPSS version 22.0 (IBM, Armonk, NY).
| PATIENTS AND METHODS
3 | RESULTS
| Patient characteristics
The study group comprised 29 males (51%) and 28 females (49%) with a mean age of 33 years (range: 6-73 years) ( 
| Treatment
Of the 40 patients with localized disease, 34 (85%) underwent limbsparing surgery. Of these 34 patients, information regarding the surgical margin was available in 25 patients (74%), which revealed that the margin was negative in 15 patients and positive in 10 patients.
Neoadjuvant and/or adjuvant chemotherapy was administered to | 761 metastasis-free survival (MFS) rates were 26% and 17%, respectively (Fig. 1B) . The univariate analysis revealed that patients with metastasis at initial presentation, at tumors of trunk origin, and without neoadjuvant and/or adjuvant therapy were significantly correlated with worse OS ( The 5-year and 10-year OS were 79% and 67%, respectively.
Patients who were treated at the primary site by surgery exhibited a significantly better 5-year OS than those treated by radiation therapy (P <0.001). Multivariate and univariate analyses showed a significant association between the worse OS and trunk origin (HR for "Yes" versus "No," 12.35; 95% CI: 1.50-101.73; P = 0.019) ( Table 3 and Fig. 2A ). The 5-year and 10-year MFS were 37% and 24%, respectively. The univariate analysis revealed that the trunk origin have a significantly worse MFS than that at other sites (P = 0.046) (Fig. 2B) . The 5-year local-recurrence free survival (LRFS) rate was 62%. The univariate analysis revealed that a tumor size of ≥8 cm and a positive surgical margin were significantly associated with a worse LRFS (P = 0.018, P = 0.009, respectively). CIRT for primary sites without excision exhibited good short-term local control ability with a 2-year LRFS of 100% in four patients. However, three of these patients (75%) finally developed LR after a mean interval of 31 months (range:
28-36 months).
The univariate analysis also revealed the neoadjuvant and/or adjuvant chemotherapy to exhibit a trend toward improvement in OS, although this was not statistically significant (P = 0.107) ( Table 3) and did not correlate with significantly better MFS (P = 0.411) or LRFS (P = 0.983).
Because the head and neck origin exhibited significantly better OS and MFS than the trunk origin (P = 0.024 and 0.014, respectively) and worse LRFS than the extremity origin (P = 0.013) (Fig. 3A-C) , we compared patient demographics and treatment data with the sites of origin to determine differences between the head and neck origin and other sites (Table 4) . Consequently, we could demonstrate that the head and neck origin was significantly associated with a higher rate of positive surgical margin (P = 0.021) and younger age (P = 0.023). This higher rate of positive surgical margin may be one of the main reasons for the high rate of LR in patients with MCS originating in the head and neck compared with that in patients with MCS originating in other sites.
| DISCUSSION
The rarity of MCS makes it difficult to draw conclusive statements regarding its clinical characteristics, prognostic factors, and ideal treatment. Our data revealed that the treatment outcomes were different depending on the site of tumor origin. Tumors originating in the trunk were associated with a significantly worse OS and MFS, and those originating in the head and neck exhibited a better OS and MFS despite difficult local control. We also found that a tumor size of ≥8 cm and a positive surgical margin were significantly correlated with worse LRFS. CIRT exhibited a short-term benefit in terms of local control. In our series, the 5-year and 10-year OS rate were 66% and 56%, respectively, among all patients, which were consistent with the previously reported unsatisfactory outcomes (5-year OS rate:
51-70% and 10-year OS rate: 37-67%). 14, 16, 17 Among the 40 patients with localized disease, the 5-year OS was 79% and 12 (29%) patients developed LR in our cohort. These data suggest that patients with MCS can have a long survival period after LR and indicate the requirement of a long-term follow-up. Of these 40 patients, 29% developed MR ≥5 years after treatment, also indicating that a long-term follow-up is highly recommended for patients with MCS. A tumor size of ≥8 cm was a significant predictor of worse LRFS. This result indicates that an early diagnosis and treatment is important for patients with MCS. We also confirmed previously published results stating that a clear margin correlates with a better LRFS. 16 This suggests that a negative margin is an important goal to pursue for patients with localized MCS.
The impact of the tumor site on survival in patients with MCS is controversial. Better survival in patients with MCS in the jaw bone 10 and worse survival in patients with MCS in the axial origin 5 have been reported. However, the largest series from EMSOS could not demonstrate a difference in prognosis among the sites of origin. 16 In the present study, the trunk origin was a significant predictor of unfavorable OS and MFS. These results may be attributed to the larger tumor size resulting from a delay in diagnosis due to the difficulty in early detection of tumors originating in the trunk (Table 4) receiving neoadjuvant and/or adjuvant chemotherapy (P = 0.057, Fig. 4) . Although further investigation with a greater number of cases is required, this result suggests that MCS originating in the trunk or extremities may undergo more frequent microscopic metastasis and be better adapted for adjuvant or neoadjuvant chemotherapy than MCS originating in the head and neck.
The role of chemotherapy has not been sufficiently investigated. The MD Anderson Cancer Centre analyzed 37 cases but failed to show a significant impact of adjuvant chemotherapy on OS, MFS, and LRFS. 17 In contrast, Cesari et al. and EMSOS found that chemotherapy was associated with a better OS and diseasefree survival. 12, 16 In the present study, neoadjuvant and/or adjuvant chemotherapy exhibited a clear trend toward improved OS when MCS was localized in the trunk or extremities.
Moreover, moderate to good responses to chemotherapy were also recorded in a neoadjuvant or palliative setting (PR in five and SD in nine out of 17 patients). We believe that the establishment of an effective adjuvant chemotherapy regimen is necessary.
Although doxorubicin for MCS was considered to be an attractive candidate agent in our study as well as that for other bone or soft tissue sarcomas, new agents, such as trabectedin for translocation-related sarcoma, may help improve the survival rate of MCS. 26, 27 The role of radiation therapy in patients with MCS has not been sufficiently investigated to date. Prior to the present study, there are | 765 no reported investigations on the efficacy of CIRT for MCS. CIRT was effective and could be the first choice of curative treatment in some subtypes of sarcoma. 28, 29 Our study suggests that CIRT may confer a short-term benefit for local control, particularly for patients with unresectable tumors, however, in most cases, long-term local control was not achieved. Further data is needed to investigate the long-term benefit of CIRT for MCS.
In conclusion, adequate surgery is considered to be the mainstay of treatment for localized MCS, and early diagnosis and treatment are essential. Prognosis was different depending on the site of tumor origin. We believe that the establishment of an effective adjuvant chemotherapy regimen is necessary to improve survival. Prospective collaborative studies are required to define the role of adjuvant chemotherapy or radiation therapy for MCS.
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FIGURE 4
Kaplan-Meier survival curve for the overall survival of localized patients in the extremities and trunk comparing those receiving neoadjuvant and/or adjuvant chemotherapy and those not receiving neoadjuvant and/or adjuvant chemotherapy
